Technical Analysis for ATXI - Avenue Therapeutics, Inc.

Grade Last Price % Change Price Change
F 3.73 2.75% 0.10
ATXI closed up 2.75 percent on Friday, May 17, 2024, on 53 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 2.75%
Boomer Sell Setup Bearish Swing Setup 2.75%
MACD Bullish Signal Line Cross Bullish 2.75%
Narrow Range Bar Range Contraction 2.75%
Wide Bands Range Expansion 2.75%
Down 3 Days in a Row Weakness 2.75%
Down 4 Days in a Row Weakness 2.75%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High 1 day ago
Up 5% 1 day ago
Up 3% 1 day ago
Up 2% 1 day ago
Up 1% 1 day ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Avenue Therapeutics, Inc. Description

Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in acquiring, licensing, developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, an intravenous formulation of tramadol hydrochloride (HCl), for the management of moderate to moderately severe postoperative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Tramadol is also combined with acetaminophen (APAP) or nonsteroidal anti-inflammatory drugs (NSAIDS) in clinical practice. During the year ending December 31, 2016, the Company had completed a pharmacokinetics (PK) study for IV Tramadol in healthy volunteers.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Drugs Chemical Compounds Chloride Opioids Analgesics Amines Neurochemistry Hepatotoxins Pharmacokinetics Paracetamol Nonsteroidal Anti Inflammatory Drug

Is ATXI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 93.75
52 Week Low 3.5157
Average Volume 72,680
200-Day Moving Average 25.29
50-Day Moving Average 8.91
20-Day Moving Average 5.29
10-Day Moving Average 4.01
Average True Range 0.82
RSI (14) 15.25
ADX 30.0
+DI 17.46
-DI 22.11
Chandelier Exit (Long, 3 ATRs) 7.87
Chandelier Exit (Short, 3 ATRs) 5.98
Upper Bollinger Bands 9.23
Lower Bollinger Band 1.35
Percent B (%b) 0.3
BandWidth 149.00
MACD Line -1.58
MACD Signal Line -1.64
MACD Histogram 0.0543
Fundamentals Value
Market Cap 139.15 Million
Num Shares 37.3 Million
EPS -2.62
Price-to-Earnings (P/E) Ratio -1.42
Price-to-Sales 0.00
Price-to-Book 2.17
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.26
Resistance 3 (R3) 4.28 4.13 4.17
Resistance 2 (R2) 4.13 4.00 4.12 4.14
Resistance 1 (R1) 3.93 3.91 3.86 3.91 4.11
Pivot Point 3.78 3.78 3.74 3.77 3.78
Support 1 (S1) 3.58 3.65 3.51 3.56 3.35
Support 2 (S2) 3.43 3.56 3.42 3.32
Support 3 (S3) 3.23 3.43 3.29
Support 4 (S4) 3.21